FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

MARKSANS

34
-1.4 (-3.95%)
Updated 03:29 03/07 IST

MARKSANS Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for MARKSANS
Disclaimer
0% Bullish
0% Bearish

MARKSANS Buy or Sell - Brokerage Reports

No. of reports in last year
0
No. of analysts
0
Average Consensus Forecast
Consensus Potential
0.00%
See MARKSANS Share Price Targets >>

MARKSANS Ratings

Long term MARKSANS rating by FrontPage users
0/5 (0 Ratings)0
Find answers to all your questions on live MARKSANS message board: Is MARKSANS buy or sell? Should I buy MARKSANS shares? Why are MARKSANS shares falling? Should I invest in MARKSANS stock?

  1. Home
  2. MARKSANS Forum

MARKSANS Share Price Discussion

Like
Reply
N
Reputation: 3,432 • Jun 8 9:21 AM
Marksans Pharma recalls 11,279 bottles of diabetes drug due to cancer causing chemical
​​The company has issued voluntary recall of one batch of Metformin extended release tablets (USP 500 mg) due to detection of NDMA (N-nitrosodimethylamine), Marksans Pharma said in a regulatory filing.
The Economic Times
Like
Reply
N
Reputation: 3,432 • Jun 8 7:18 AM
Marksans Pharma recalls 11,279 bottles of diabetes drug due to cancer causing chemical
The company has issued voluntary recall of one batch of Metformin extended release tablets (USP 500 mg) due to detection of NDMA (N-nitrosodimethylamine), Marksans Pharma said in a regulatory filing.
Moneycontrol
Like
Reply
S
Reputation: 9,236 • Jun 2 5:04 AM

Type
Buy
Instrument
MARKSANS
Entry Price
₹26.3
Price@Trade
₹26.3
Target Price
₹40
Stop Price
₹23
Valid Till
Jul 2, 2020 3:20 AM
Margin
₹26,300 approx for 1000 Qty
Status
Exited
Exit Price
₹32.1
Net P&L
+₹5,800 (+22.05%)
Like
Reply (1)
Latest replies
Sanjeev @sanjeev6261
Jun 9 3:45 AM

Update
Exited
Exit Price
₹32.1
Net P&L
+₹5,800 (+22.05%)

BUY MARKSAN PHARMA @ 25-26, STRICT SL 23, TGT 35-40 ( 8-10 day #MARKSANS
Like
Reply
S
Reputation: 3,164 • May 19 2:49 AM

Type
Buy
Instrument
MARKSANS
Entry Price
₹20.25
Price@Trade
₹20.25
Target Price
₹24
Stop Price
₹18
Valid Till
May 19, 2020 3:20 AM
Margin
₹60,750 approx for 3000 Qty
Status
Exited
Exit Price
₹20.25
Net P&L
₹0 (0%)
Like
Reply (1)
Latest replies
Sam Sir @samsirs
May 19 3:19 AM

Update
Exited
Exit Price
₹20.25
Net P&L
₹0 (0%)
N
Reputation: 3,432 • Feb 11 6:38 AM
Marksans Pharma gets EIR from USFDA for New York unit
In a regulatory filing, the company announced "receipt of the EIR from US Food and Drug Administration (USFDA) in respect of inspection of company's manufacturing facility Time-Cap Laboratories Inc. located at Farmingdale, New York, USA carried out from December 5, 2019 to December 18, 2019".
Moneycontrol
Like
Reply
T
Reputation: -15,815 • Jan 22 4:14 AM
MARKSANS

Type
Buy
Instrument
MARKSANS
Entry Price
₹19.6
Price@Trade
₹19.6
Target Price
₹24.45
Stop Price
₹18.8
Valid Till
Feb 20, 2020 3:20 AM
Margin
₹19.6 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹18.8
Net P&L
-₹0.8 (-4.08%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Jan 30 2:50 AM

Update
Stoploss Hit
Exit Price
₹18.8
N
Reputation: 3,432 • Jun 6, 2019 10:08 AM
Like
Reply
N
Reputation: 3,432 • Jun 6, 2019 9:38 AM
Like
Reply

Marksans Pharma reported better than street estimates of Q3 results. Company reported Q3 net profit Rs251.3mn (up 44% YoY), EBITDA margin 14.5% vs 13.2% (QoQ) and sales Rs2.48bn (up 14% YoY)
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • MARKSANS - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization1,295.43
    Enterprise Value1,361.58
    Price to Earnings104.22
    Price to Book Value3.02
    Return on Capital Employed0.05
    Return on Equity0.03
    Face Value1
    Dividend YieldNA
  • MARKSANS - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    11-Jun-18CentrumHold31
    22-Feb-18CentrumBuy55
    30-Sep-16Dynamic LevelsBuy70
    29-Sep-16CentrumBuy60
    MARKSANS Brokerage Price Target
  • MARKSANS Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 335.635.6533.7534.05
    Jul 235.4535.453435.4
    Jul 132.933.831.6533.8
    Jun 3033.13432.0532.2
    Jun 293535.1533.5533.55
  • MARKSANS Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹33.52
    30 Day Moving Average₹30.57
    50 Day Moving Average₹26.26
    100 Day Moving Average₹21.64
    200 Day Moving Average₹18.65
  • MARKSANS - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue294.66215.840.37
    Operating Profit36.4524.190.51
    Profit Before Tax16.6512.580.32
    Net Income12.4312.230.02
  • MARKSANS - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds428.97430.03-0
    Total Liabilities127.28128.45-0.01
    Total Assets556.25547.480.02
  • MARKSANS - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity23.17-18.67-2.24
    Cash from Investing Activity-7.52-7.8-0.04
    Cash from Financing Activity-17.525.9-1.68
    Net Cash Flow-1.85-0.572.25
  • MARKSANS - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.020.02
    Return on Equity0.030.03
    Return on Capital Employed0.050.03
  • MARKSANS - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.27
    3 Year CAGR Growth in Operating Profit-0.69
    3 Year CAGR Growth in EBIDTA-0.69
    3 Year CAGR Growth in Net Income-0.81
    3 Yr CAGR Growth - Diluted EPS-0.82
  • MARKSANS - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.53
    5 Year CAGR Growth in Operating Profit-0.18
    5 Year CAGR Growth in EBIDTA-0.24
    5 Year CAGR Growth in Net Income-0.69
    3 Yr CAGR Growth - Diluted EPS-0.71
  • MARKSANS - Recent News

    keyboard_arrow_down
    NewsBot
    Jun 8 9:21 AM
    Marksans Pharma recalls 11,279 bottles of diabetes drug due to cancer causing chemical
    The Economic Times
    NewsBot
    Jun 8 7:18 AM
    Marksans Pharma recalls 11,279 bottles of diabetes drug due to cancer causing chemical
    Moneycontrol
    NewsBot
    Feb 11 6:38 AM
    Marksans Pharma gets EIR from USFDA for New York unit
    Moneycontrol
    NewsBot
    Jun 6, 2019 10:08 AM
    NewsBot
    Jun 6, 2019 9:38 AM
    NewsBot
    Mar 7, 2019 7:52 AM
    NewsBot
    Nov 17, 2018 10:47 AM
  • MARKSANS - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020